UBS Group’s F/m Emerald Life Sciences Innovation ETF LFSC Stock Holding History

UBS Group’s Portfolio LFSC Stock Details LFSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21	Closed	-$735	–	11288
2026 Q1	$735	Sell	21 -324	-94%	-$11.5K	﹤0.01%	9768
2025 Q4	$12.6K	Buy	+345	New	+$11.8K	﹤0.01%	8100
2025 Q3	–	Sell	-853	Closed	-$21K	–	11210
2025 Q2	$21K	Buy	853 +845	+10,563%	+$19.3K	﹤0.01%	8394
2025 Q1	$180	Buy	+8	New	+$195	﹤0.01%	9898

Other funds holding LFSC

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

CCWP

Cedar Cove Wealth Partners Bloomington, Minnesota $213M AUM

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $9.98B AUM 26.5% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

OPA

Old Port Advisors Portland, Maine $508M AUM 50.99% 1-Year Est. Return

Tidal Investments Milwaukee, Wisconsin $57.8B AUM 72.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group's LFSC Position: Q2 2026 in Review

UBS Group sold out of F/m Emerald Life Sciences Innovation ETF (LFSC) in Q2 2026, closing a stake of 21 shares — an estimated $735 sold.

UBS Group first reported a position in LFSC in Q1 2025 and held it in 4 quarters. The position peaked at $21K in Q2 2025. 8 funds tracked by Wall St. Rank hold LFSC as of Q2 2026.

UBS Group reported no remaining F/m Emerald Life Sciences Innovation ETF position as of Q2 2026 after selling out during the quarter.
UBS Group sold 21 F/m Emerald Life Sciences Innovation ETF shares in Q2 2026, an estimated $735.
UBS Group first reported a position in F/m Emerald Life Sciences Innovation ETF in Q1 2025 and held it in 4 quarters.
UBS Group's F/m Emerald Life Sciences Innovation ETF position peaked at $21K in Q2 2025.
8 funds tracked by Wall St. Rank held F/m Emerald Life Sciences Innovation ETF as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.